bcl-2

(redirected from Bcl-2 gene)
Also found in: Medical, Wikipedia.

bcl-2

(biochemistry)
A family of proteins that operate in the effector phase of apoptosis and may either promote or inhibit apoptosis.
References in periodicals archive ?
00 units/ml of plasma P53 gene expression: 10-50 units/ml of plasma Bcl-2 gene expression: 10 units BAX gene expression: 10-100 units Survivin gene expression: 10 units P21 gene expression: 10-50 units P53 protein level units/ml of plasma No Date of blood Wild P53 Ref.
Translocation of the BCL-2 gene on chromosome 18q21 results in constant inactivation of apoptosis (3).
55[degrees]C/1 min, 72[degrees]C/1 min and a final extension of 72[degrees]C/10 min for [beta]-Actin and Bcl-2 gene.
Clinical significance of bcl-2 gene expression in human breast cancer tissues, Breast Cancer Res.
Transient Bcl-2 gene down-expression in circulating mononuclear cells of severe sepsis patients who died despite appropriate intensive care.
We also demonstrated statistically significant, dose-dependent, and specific knockdown of the Bcl-2 gene with suppression of protein levels up to 60 percent," said Dr.
Importantly, the Trinity team also discovered that members of the Bcl-2 gene family could override this process, switching off the self-eating process and leading to survival of cancerous cells.
6) More than 85% of FLs in adults demonstrate a characteristic translocation, t(14;18)(q32;q21), involving the bcl-2 gene,16 whereas most pediatric FLs are negative for bcl-2 protein and lack bcl-2/immunoglobulin heavy chain (IgH) translocations.
HL-60bcl-2 cells, which are derived from a stable transfectant clone of the human bcl-2 gene into the HL-60 leukemia cell line, show 5-fold greater expression of the Bcl-2 protein compared with HL-60neo cells, a control clone transfected with vector alone.
In contrast, dioxins cause a more prolonged atrophy of the thymus that is only slightly ameliorated by expression of the Bcl-2 gene.
Although a positive control for detecting the bcl-2 gene rearrangement, SU-DHL-4, is commercially available as DNA, we have been unable to obtain the cell line.
The claims cover the use of antisense targeted to the bcl-2 gene, which includes Genta's lead drug candidate G3139, to sensitize cancer cells or to kill cancer cells with bcl-2 antisense, either alone or in combination with chemotherapy agents.